Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
ADACTA trial: Tocilizumab more effective than adalimumab in treating RA

ADACTA trial: Tocilizumab more effective than adalimumab in treating RA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Functional disability impacts educational attainment in children with JIA

Functional disability impacts educational attainment in children with JIA

Juvenile Arthritis patients may have difficulties achieving educational success

Juvenile Arthritis patients may have difficulties achieving educational success

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Adalimumab may decrease vascular inflammation in patients with psoriasis

Adalimumab may decrease vascular inflammation in patients with psoriasis

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Preliminary results from Genentech's ACTEMRA monotherapy study on RA

Preliminary results from Genentech's ACTEMRA monotherapy study on RA

NHS approves new rheumatoid arthritis drug RoActemra

NHS approves new rheumatoid arthritis drug RoActemra

Juvenile arthritis affected kids are at a high risk of cancer: Study

Juvenile arthritis affected kids are at a high risk of cancer: Study

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

TNF inhibitors may minimally increase risk of serious infections

TNF inhibitors may minimally increase risk of serious infections

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Link between use of anti-TNF therapy and malignant melanoma in RA patients

Link between use of anti-TNF therapy and malignant melanoma in RA patients

Doctors may stop anti-TNF medications for RA patients before surgery to reduce disease flares

Doctors may stop anti-TNF medications for RA patients before surgery to reduce disease flares

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.